Cardiff Oncology Is Maintained at Overweight by Piper Sandler

Dow JonesDec 13 21:24 · Ratings

Cardiff Oncology Analyst Ratings

BenzingaDec 13 21:13 · Ratings

Piper Sandler Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Raises Target Price to $10

Futu NewsDec 13 20:31 · Ratings

TD Cowen Maintains Cardiff Oncology(CRDF.US) With Buy Rating

Futu NewsDec 13 20:31 · Ratings

Cardiff Oncology Director Gary Pace Buys $940,199 in Stock

InvestingDec 13 05:10

CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study

Zacks Dec 11 22:30